Cabaletta Bio (NASDAQ:CABA) executives told investors at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company has initiated enrollment in what it described as its first pivotal program ...

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

About Cabaletta Bio Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 antitrypsin deficiency landscape is coming into focus, with Wave and Beam ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Investing.com - Guggenheim has reiterated a Buy rating and $15.00 price target on Cabaletta Bio Inc. (NASDAQ:CABA), highlighting the company’s differentiated commercial strategy for its rese-cel ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cabaletta Bio, Inc. (CABA) is a stock that can certainly grab the ...

Cellares recently announced that Cabaletta Bio’s investigational CAR T therapy rese-cel received FDA clearance of an IND amendment to use its fully automated Cell Shuttle and Cell Q platforms for ...

Furthermore, H.C. Wainwright has maintained a Buy rating on Cabaletta Bio, setting a price target of $16.00, following the presentation of positive clinical data from the RESET trials. These trials, ...

Michael Gerard, General Counsel of Cabaletta Bio, Inc. (NASDAQ:CABA), recently purchased 6,600 shares of the company’s common stock. The transactions, which occurred on January 21, 2026, involved a ...